ADC quantification to classify patients candidate to receive bevacizumab treatment for recurrent glioblastoma

BackgroundRecurrent high-grade gliomas progressing after surgery and temozolomide plus radiation therapy have traditionally been treated using antiangiogenic drugs as the first-line therapy. Since ...